HK1036214A1 - Oral delivery of chemically modified proteins - Google Patents

Oral delivery of chemically modified proteins

Info

Publication number
HK1036214A1
HK1036214A1 HK01105975A HK01105975A HK1036214A1 HK 1036214 A1 HK1036214 A1 HK 1036214A1 HK 01105975 A HK01105975 A HK 01105975A HK 01105975 A HK01105975 A HK 01105975A HK 1036214 A1 HK1036214 A1 HK 1036214A1
Authority
HK
Hong Kong
Prior art keywords
chemically modified
oral delivery
modified proteins
csf
pegylated
Prior art date
Application number
HK01105975A
Other languages
English (en)
Inventor
Alan D Habberfield
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1036214A1 publication Critical patent/HK1036214A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK01105975A 1994-02-08 2001-08-23 Oral delivery of chemically modified proteins HK1036214A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19418794A 1994-02-08 1994-02-08
US37912195A 1995-02-01 1995-02-01

Publications (1)

Publication Number Publication Date
HK1036214A1 true HK1036214A1 (en) 2001-12-28

Family

ID=26889779

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01105975A HK1036214A1 (en) 1994-02-08 2001-08-23 Oral delivery of chemically modified proteins

Country Status (12)

Country Link
US (2) US20020099001A1 (el)
EP (2) EP1090645B1 (el)
AT (2) ATE311908T1 (el)
AU (1) AU1916295A (el)
DE (2) DE69534676T2 (el)
DK (2) DK1090645T3 (el)
ES (2) ES2251924T3 (el)
GR (1) GR3036625T3 (el)
HK (1) HK1036214A1 (el)
IL (1) IL112583A0 (el)
PT (1) PT726778E (el)
WO (1) WO1995021629A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885567A (en) * 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
AU766190B2 (en) 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
IL142282A0 (en) 1998-10-16 2002-03-10 Biogen Inc Compositions containing polymer conjugates of interferon-beta-1a
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
MXPA02006795A (es) 2000-01-10 2005-04-19 Maxygen Holdings Ltd Conjugados g-csf.
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
PL1633440T3 (pl) * 2003-04-15 2008-12-31 Opperbas Holding Bv Kompozycja farmaceutyczna zawierająca białka i/lub polipeptydy oraz cząstki koloidalne
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
RU2007149238A (ru) 2005-06-01 2009-07-20 Максиджен Холдингз Лтд. (Ky) Пегилированные полипептиды гксф и способы их получения
KR100694994B1 (ko) 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
AU2008292186B9 (en) 2007-08-27 2014-07-03 Ratiopharm Gmbh Liquid formulation of G-CSF conjugate
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
WO2018085495A2 (en) * 2016-11-02 2018-05-11 Board Of Regents, The University Of Texas System Dissolvable films and methods of their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2792862B2 (ja) * 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
DE69120141T2 (de) * 1990-03-28 1996-11-28 Shuji Kojima Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods

Also Published As

Publication number Publication date
EP1090645A3 (en) 2002-02-27
ATE311908T1 (de) 2005-12-15
ATE203415T1 (de) 2001-08-15
WO1995021629A1 (en) 1995-08-17
AU1916295A (en) 1995-08-29
ES2251924T3 (es) 2006-05-16
GR3036625T3 (en) 2001-12-31
ES2159630T3 (es) 2001-10-16
DK1090645T3 (da) 2006-03-27
DE69521880T2 (de) 2002-01-03
EP1090645A2 (en) 2001-04-11
PT726778E (pt) 2001-12-28
EP1090645B1 (en) 2005-12-07
US20030185795A1 (en) 2003-10-02
EP0726778A1 (en) 1996-08-21
EP0726778B1 (en) 2001-07-25
DK0726778T3 (da) 2001-09-24
US20020099001A1 (en) 2002-07-25
IL112583A0 (en) 1995-05-26
DE69534676T2 (de) 2006-08-17
DE69521880D1 (de) 2001-08-30
DE69534676D1 (de) 2006-01-12

Similar Documents

Publication Publication Date Title
IL112583A0 (en) Oral delivery of chemically modified proteins
KR100261030B1 (en) N-terminally chemically modified protein compositions and methods
HK1245320A1 (zh) 治療缺陷α半乳糖苷酶A的藥物製劑
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
HU9701437D0 (en) Use of complex lipides as stabilizing additives in pharmaceutical compositions containing digestive anzymes
NZ504771A (en) IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)
ZA954331B (en) Compounds and compositions for administration via oral inhalation or insufflation
IL106591A0 (en) An interferon alpha/beta binding protein,its preparation and pharmaceutical compositions containing it
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
EP1878794A3 (en) Compositions and methods for the treatment of immune related diseases
ZA935120B (en) Medicinal compositions for the improvement of blood coagulation comprising TCF-II
ZA879325B (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
IT1264830B1 (it) Agenti per l'ossigenazione extracorporea del sangue
IL101313A0 (en) Compositions and methods for increasing oxygen delivery to tissue

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20150207